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ABSTRACT 
 
Background: Many recent epidemiological studies have shown that epileptic patients are more likely suffer from 
depression, anxiety, and irritability. However, the cellular mechanisms of epilepsy-induced psychotic behaviors 
are not fully elucidated. Neurotrophin receptors have been suggested to be involved in epilepsy and also in 
psychiatric disorders. Up-regulation of p75NTR expression and activation of p75NTR signalling cascades after the 
seizure have been shown, but the role of the p75 receptor in epilepsy-induced psychotic behaviors has not been 
documented so far. Therefore, the present work aimed to investigate the effect of p75 receptor blockade on 
seizure activity, irritability, and anxiety-like behaviors in a rat model of status epilepticus. Methods: Rats were 
injected with pilocarpine (350 mg/ kg, i.p.) to induce status epilepticus. Then various behavioral tests were 
performed after the blockade of p75NTR alone or in combination with p75 antagonist and phenobarbital. 
Molecular analysis by PCR was performed to investigate the expression of p75 and pro-NGF. Results: Molecular 
findings indicated a high level of mRNA expression for both p75 receptors and pro-NGF in the epileptic model 
group. Results also showed that the administration of p75 antagonist alone or in combination with phenobarbital 
was able to significantly influence the behavioral responses. Furthermore, 20-hours video monitoring showed a 
decrease in the frequency and duration of seizures in the rat group receiving p75 antagonist. Conclusion: Taken 
together, the present study suggests that the blockade of the p75 receptor may affect the irritability and anxiety-
related behavior in a rat model of status epilepticus. DOI: 10.22034/ibj.22.4.264 
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INTRODUCTION 
 
Pilepsy is one of the most common neurological 
disorders with a prevalence of 1% in the general 
population. This disorder is associated with the 
excessive electrical discharges in the neurons. Studies 
have shown that the prevalence of psychiatric disorders 
in patients with epilepsy is more frequent than that in 
general population
[1,2]
. More than one in four epileptic 
patients have experienced psychological problems, E 
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which might need treatment, and more than 10% of 
patients in psychiatric hospitals are diagnosed with 
epilepsy
[3]
. Seizure is related with neurological and 
behavioral problems such as anxiety, memory 
impairment, psychosis, and cognitive dysfunction, 
which affect the quality of life of patients
[4-6]
. 
Several lines of evidence have indicated that nerve 
damage and sclerosis occur in different areas of the 
brain, especially in the hippocampus of patients with 
temporal lobe epilepsy (TLE)
[7-10]
. Thus, after the 
initial damages, this area could be considered as the 
origin of spontaneous seizures. In addition, since the 
hippocampus, as a part of the limbic system, plays an 
important role in learning and memory and mood 
stability, its destruction can cause behavioral 
abnormalities such as fear, anxiety, depression, 
memory impairment, and hyperexcitability
[11]
. In TLE, 
hyperexcitability and neuronal loss in hippocampus 
evoke psychiatric problems, such as mood 
disturbances. On the other hand, hippocampal atrophy 
and synaptic disturbances, which occur in depression, 
increase neuronal excitability, thereby leading to 
TLE
[12]
. Therefore, epilepsy and neuropsychiatric 
disorders may have common pathophysiological 
mechanisms. 
The involvement of neurotrophins in several nervous 
system disorders, including epilepsy and 
neuropsychiatric disorders, has been reported
[13,14]
. 
Neurotropic factors have been considered as important 
candidates for therapeutic intervention against 
neurological diseases. Considering the important role 
of these factors in the nervous system, investigation of 
their signalling pathways and ligand-receptor 
interactions is essential. One of these signalling 
pathways is related to the function of p75 neurotrophin 
receptors, which is a transmembrane receptor for tumor 
necrosis family of growth factors, including nerve 
growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotropic 3 (NT3) and neurotropic 4 
(NT4)
[15,16]
 . 
Previous studies have reported that high affinity of 
pro-neurotrophins to p75 receptors increases the rate of 
neuropsychiatric diseases including depression
[17]
. 
These receptors are widely expressed throughout the 
brain in embryonic periods. Hippocampal neurones 
also express p75 receptors in various stages of 
development
[18]
. Expression of the p75 receptor is 
increased in the hippocampus after seizures as well as 
in the forebrain cholinergic neurons following damages 
due to the excessive excitability of these neurons. In 
addition to this, re-expression of p75 in the 
aforementioned cells may be a part of damage-induced 
plasticity, which will start the mechanism of 
evolutionary recapitulation in the case of lesions and 
stressors, leading to the production of pro-NGR in 
some brain areas where p75-dependent cell death may 
occur
[19-23]
. 
p75 re-expression has been indicated to be a part of a 
homeostatic program to destroy neurons, axons, and 
synapses in the degenerated or damaged areas
[24]
. 
Therefore, it seems quite logical that the p75 signalling 
pathway can be regarded as a therapeutic target for 
these conditions and has to be taken into consideration. 
The reason for this consideration might be that 
epilepsy comorbidity with the most psychiatric 
disorders in epileptic patients is struggling with these 
issues
[17,25]
. This comorbidity has still not been well 
defined, and the relationship between epilepsy and 
psychiatric disorders has not been fully determined 
although some attempts have been made to find a 
correlation between epilepsy and mental health 
problems
[26]
. Various animal models have been 
developed for the study of epilepsy, and among them, 
pilocarpine-induced epilepsy is one of the most 
common models in the rodent. In this model of 
epilepsy, development of spontaneous seizure results in 
behavioral disturbances, which may take three weeks 
up to three months after pilocarpine-induced status 
epilepticus. Investigations performed on the 
pilocarpine model have reported that epilepsy can be 
divided into three stages: acute, latent, and 
chronic
[27,28]
. However in two recent studies, this 
concept was changed, so that in the first days after 
induction of seizures, epilepsy was divided into the 
immature and mature phases, where the onset of 
aggression and agitation in behavior coincided with the 
mature phase of seizures
[29,30]
. 
The present study, by using molecular and behavioral 
approaches, aimed to answer two questions: The first 
one is what would be the behavioral consequences of 
enhancement of p75 and pro-NGF levels in the animal 
model of TLE induced by pilocarpine, and the second 
one is whether p75 receptor blockade can be effective 
on behavioral changes induced by pilocarpine 
injection. 
 
 
MATERIALS AND METHODS 
 
Animals  
Adult male Wistar rats, provided by Shahid Beheshti 
University Animal House (Tehran, Iran), were housed 
under controlled standard conditions (12 h light/dark 
cycle), with food and water available ad libitum a week 
before.  Rats were divided into three main groups (n = 
7 rats in each group), including the control group, 
vehicle-treated group, and pilocarpine-treated group. 
The pilocarpine-treated group was further subdivided 
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into four groups (pilo-treated alone, pilo-treated+p75 
antagonist, pilo-treated + p75 antagonist + 
phenobarbital, and pilo-treated + pheno-barbital; n = 7 
rats were assigned for each group. The dose of P75 
antagonist was chosen based on previous studies
[31,32]
. 
All experiments were performed in accordance with 
the animal care and management rules approved by the 
Ethics Committee of Iran University of Medical 
Sciences (Tehran, Iran). 
 
Drugs and chemicals 
Phenobarbital was purchased from Temad Co. 
(Tehran, Iran). Pilocarpine hydrochloride and 
scopolamine methyl nitrate were procured from Sigma-
Aldrich (St. Louis, MO, USA). p75 neurotrophic factor 
antagonist peptide was synthesized and purchased from 
GenScript, USA, with a minimum 92.9% purity.  
 
Induction of pilocarpine model of epilepsy 
To induce epilepsy, rats were injected with 
pilocarpine hydrochloride (380 mg/kg, i.p.; Sigma-
Aldrich, UK), a muscarinic cholinergic agonist. In 
order to prevent the peripheral cholinergic effects of 
pilocarpine, rats were pre-treated with scopolamine 
methyl nitrate, as a cholinergic antagonist (1 mg/kg, 
i.p.; Sigma-Aldrich, UK) 30 minutes before the 
injection of a single dose of pilocarpine hydrochloride. 
Then the treated rats were monitored for a period of 3 
to 4 hours after injection of pilocarpine, and the seizure 
severity was graded according to Racine’s criteria
[33]
. 
Only rats were included in the present work if they 
exhibited stage 4 or 5 seizure score. In order to 
terminate the sustained seizure that lasted for 3 hours, 
diazepam (7 mg/kg, i.p.) was injected, and an 
additional dose of diazepam (3 mg/kg, i.p.) was 
administered every 2 hours, if needed, and then the 
animals were cared and fed with Hartmann’s solution 
till recovery
[34]
. Two weeks after pilocarpine injection, 
the occurrence of spontaneous seizures was recorded 
during chronic phase using daily video monitoring 8 
hours/day for two weeks. 
 
Behavioral assessment 
Excitability and sensory responsiveness of control 
and pilocarpine-treated rats were evaluated using 
different behavioral tests, including approach-response, 
touch-response, finger-snap, and pick-up tests as 
described by Huang et al.
[35]
. Behavioral assessments 
were performed two weeks after status epilepticus 
induction between 9 a.m. and 12.30 p.m. Three groups 
of epileptic rats were randomly selected for i.p. 
injection of p75 antagonist alone (1 mg/kg dissolved in 
normal saline; n = 7) or an injection of phenobarbital 
alone (30 mg/kg, dissolved in normal saline; n = 7), or 
co-administration of p75 antagonist and phenobarbital 
with 30 minutes interval between injection of 
phenobarbital and p75 antagonist. All injections and 
tests were done for six days that were performed in the 
home cage with 30-min intervals between each test
[36]
.  
 
Approach-response test 
A pen held vertically was moved slowly toward the 
face of the animal, and responses were scored as 1, the 
rat had no reaction; 2, the rat sniffed at the pen; 3, the 
rat moved away from the pen; 4, the rat was frozen; 5, 
the rat jumped away from the pen; 6, the rat jumped at 
or attacked the pen. 
 
Touch-response test 
The animal was gently prodded in the rump with the 
blunt end of a pen. Responses were recorded as 1, the 
rat has no reaction;  2, the rat turned toward the object; 
3, the rat moved away from the object; 4, the rat 
frozen; 5, the rat turned toward the touch;  6, the rat 
turned away from the touch; 7, the rat jumped with or 
without vocalizations
[35,37]
. 
 
Finger-snap test 
A finger snap several inches above the head of the 
animal was performed. Responses were scored as 1, the 
rat had no reaction; 2, the rat jumped slightly (normal 
reaction); 3, the rat jumped suddenly
[35,38]
. 
 
Pick-up test 
The animal was picked up by grasping around the 
body. Responses were scored as 1, very easy; 2, easy 
with vocalizations; 3, some difficulties, the rat reared 
and faced the hand; 4, frozen (the rat); 5, difficult, the 
rat avoided the hand by moving away; 6, very difficult, 
the rat behaved defensively and may attacked the 
hand
[35,37]
. The behavioral tests were done by three 
independent observers, and the means of their scores 
were calculated for each animal for each test.  
 
Video monitoring of behavioral seizure 
 To evaluate the frequency and duration of 
spontaneous recurrent seizures (SRS), the rats were 
videotaped and then reviewed by an investigator 
blinded to treatment groups to score the number and 
cumulative duration of tonic-clonic seizures. Origin 7.5 
SR6 (Microcal Software, Northampton, MA, USA) 
software was used for data recording and analysis. 
Power spectrum analysis was performed after applying 
a Hamming window function
[39]
. 
 
Elevated plus maze 
For assessing anxiety-related behavior and agitation, 
elevated plus maze test was performed in which maze 
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was made of black-painted wood with four elevated 
arms raised by a single central support to a height of 62 
cm above the floor. It was arranged as a cross with two 
open arms (45 × 10 cm) facing each other, and two 
other arms enclosed by high walls (45  10  40 cm). 
The four arms extended from a common central 
platform (10  10 cm). Ridges of 0.5 cm bordering the 
open arms were added to provide an additional grip. 
Behavior on the maze was recorded by a video camera 
mounted above the plus maze apparatus and connected 
to a monitor and a video tracking, motion analysis and 
behavior recognition system (EthoVision®, Noldus, 
Wageningen, Netherlands) in a room under low-
intensity light (20  l). The maze was divided into five 
areas, one for each arm and one for the centre (central 
platform). Programming and data recording equipment 
were controlled by a computer
[40]
. 
 
Real-time RT-PCR analysis of mRNA expression  
The mRNA level p75 and pro-NGF genes in 
hippocampal tissue were determined in different 
groups of rats (n = 4 for each group). The rats were 
sacrificed at one week, two weeks, and three weeks 
after the induction of TLE model by pilocarpine, and 
then hippocampal tissue was dissected over cold PBS. 
Briefly, total cellular mRNA was isolated using 
QIAzol, according to the manufacturer’s protocol. The 
quantity and quality of the isolated RNA was assessed 
by Spectrophotometery (Ultrospec 2000 UV/VIS 
spectrophotometer,Pharmacia Biotech, Freiburg, 
Germany). cDNA was generated from 1 µg of total 
RNA by reverse transcription using the cycle script 
reverse transcription system (Bioneer, Korea). The 
mRNA expression levels of p75NTR and pro-NGF and 
GAPDH were determined by quantitative real-time 
RT-PCR, using a Rotor-Gene 6000 Real-Time Thermal 
Cycler (Qiagen, Germany). GAPDH mRNA was used 
as the internal control. The PCR reactions were set up 
in a volume of 10 µL containing 1 µL cDNA, 5 µL 
AccuPower® 2X GreenStar qPCR Master Mix 
(Bioneer, Korea) and 10 pM of each forward and 
reverse specific primer. Reaction mode was set at  
95 °C for 10 min, followed by 40 cycles of 95 °C for 
15 s and 60 °C for 1 min. Amplification specificity was 
checked using verifying a single peak in melting 
curves. All samples and controls were normalized to 
the reference gene. No template controls and no 
reverse transcriptase control were included in each 
PCR run. All assays were carried out three times as 
independent PCR runs for each cDNA sample. The 
ΔΔCT method
[41]
 was used to quantify the 
amplification-fold difference between groups; each 
gene expression was normalized with respect to 
GAPDH mRNA content. To validate the use of ΔΔCT 
method, a 5-fold serial dilution was performed on a 
cDNA sample over a 125-fold range. For each dilution 
sample, amplifications were performed in triplicate 
using reference and target gene primers. The average 
CT of all tests was calculated, and the ΔCT of target 
(p75NTR anf pro-NGF) and reference (GAPDH) genes 
were determined. A plot of the log cDNA dilution 
versus ΔCT (ΔCT target-ΔCT reference) was made for 
each target and reference genes, and the slope of fitted 
line was determined
[39]
. 
 
Statistical analysis 
All statistical analyses were performed using SSPS 
19.0 (SPSS Inc., Chicago, IL, USA) and Prism 
software (version 6.0). Two-way analysis of variance 
(ANOVA) with Bonferroni’s post hoc’s test was used 
to examine significant differences between the groups. 
All results are presented as mean values ± standard 
error of mean (SEM), and p < 0.05 was considered as 
statistically significant difference. 
 
 
RESULTS 
 
Behavioral changes associated with status 
epilepticus  
Since p75NTR is up-regulated following induction of 
SE
[42]
 and may be involved in several psychiatric 
diseases
[17,25]
; therefore, we here asked whether the 
blockage of p75NTR would ameliorate behavioral 
changes associated with pilocarpine treatment in a rat 
model of SE. Findings showed that pilocarpine-treated 
rats exhibited significantly higher scores for aggression 
and anxiety in the approach and in the touch-response 
tests. In the approach-response test, the average score 
in control rats was 2.07 ± 0.21 versus 4.59 ± 0.19 in the 
pilocarpine-treated rats (p < 0.001; Fig. 1A). In the 
touch-response test, the average score for control rats 
was 2.11 ± 0.20 versus 5.40 ± 0.34 in the pilocarpine-
treated rats (p < 0.001; Fig. 1B). Similarly, in the 
finger-snap test, epileptic rats were more disturbed, 
showing the higher levels of anxiety and restlessness 
(2.52 ± 0.19) as compared to the control rats (1.42 ± 
0.19, p < 0.001; Fig. 1C). In the pick-up test, the mean 
score was significantly elevated in pilocarpine-treated 
rats (4.57 ± 0.36, p < 0.001) when compared to control 
rats (2.09 ± 0.20; Fig.1D). These results indicated that 
epileptic rats displayed significantly the increased 
levels of aggressive behavior compared to the control 
rats. Next, the effects of p75NTR antagonist treatment 
alone or in combination with phenobarbital on 
behavioral responses were investigated. Pilocarpine-
treated rats were given daily i.p. injection of p75NTR 
antagonist alone, phenobarbital alone, or a combination  
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Fig. 1. Behavioral assessment of P75NTR blockage in a rat model of pilocarpine-induced status epilepticus using approach-response 
(A), touch-response (B), finger-snap (C), and pick-up (D) on six days following SE induction. Bars represent mean ± SEM of the 
score. Two-way ANOVA was followed by post hoc comparisons using the Bonferroni's method between control, pilocarpine-treated, 
pilo + P75 antagonist, pilo + phenobarbital, and pilo + P75 antagonist+phenobarbital. *represents significant difference between all 
treated groups and the control rats (p < 0.05, p < 0.01, p < 0.001) and † shows significant difference between pilocarpine-treated 
rats and the control and other treated animals (†p < 0.05, ††p < 0.01). 
 
 
of both   for six  days and then behavioral tests  were 
performed  over   a  period  of  six  days,  starting  from 
the second weeks after the induction of SE. The results 
of the behavioral tests showed that treatment with 
p75NTR antagonist alone or with phenobarbital 
improved the behavioral responses in approach resulted 
in a significant lowered mean scores when compared 
with pilocarpine-treated alone rats during days 5-6 (p < 
0.001; Fig. 1A). Blockade of p75NTR and treatment 
with combined p75NTR antagonist and phenobarbital 
led to a significant decrease in the touch-response score 
at 5-6 days (p < 0.001, Fig. 1B). Phenobarbital 
treatment alone did not affect the aggressive behavioral 
scores compared to the epileptic rats (Figs. 1A and 
1B).  Hypersensitive responses of epileptic rats were 
also evident both in the finger-snap and pick-up tests 
(Figs. 1C and 1D), and treatment with p75NTR 
antagonist alone or in combination with phenobarbital 
significantly reduced the behavioral hyperexcitability 
in epileptic rats on days 5 and 6 (p < 0.001; Figs. 1C 
and 1D). However, there were no significant 
differences between either p75NTR antagonist 
treatment alone or when co-treated with phenobarbital 
and control animals in all performed tests. 
 
Duration and frequency of spontaneous recurrent 
seizures  
Two weeks after SE induction, continuous 20 hours 
video monitoring was used, and the average of 
frequency and duration of SRS was investigated 
following the blockade of p75NTR. The results 
showed that p75NTR blockade by antagonist injection 
alone or combined with phenobarbital markedly 
reduced the frequency and duration of the recurrent 
seizures, whereas phenobarbital treatment alone had no 
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significant effect on either the frequency or duration of 
SRS (Fig. 2).  
 
Anxiety-related behaviors induced by pilocarpine  
In elevated plus maze test, the open-arm entrance  
and time spending on the open arms of the maze  were 
considered as a measure of the stress level
[43]
. In the 
epileptic rats, the percentage of time spent in open arm 
was significantly longer (33.88 ± 3.24; p < 0.05) 
compared to control rats (17.8 ± 2.7; Fig. 3A). In 
addition, a significant increase in the percentage of 
entries in open arm was observed in the epileptic rats 
(35.9 ± 5.2; p < 0.05) when compared to the controls 
(20.01 ± 2.9; Fig. 3B). Treatment with p75NTR 
antagonist alone or combined with phenobarbital had a 
significant shortening effect on the percentage of time 
spent in the open arm compared with pilocarpine-
treated alone rats (18.11 ± 4.9 and 19.4 ± 1.3, for pilo + 
p75 antagonist and pilo + p75 antagonist + pheno; p < 
0.05; Fig. 3A). However, phenobarbital treatment 
alone had no significant effect on the time spent in 
open arm compared with the epileptic rats. Also, the 
treatment of epileptic rats with p75 antagonist (24.8 ± 
4.9) or phenobarbital alone (26.04 ± 1.7), but not in 
combination with phenobarbital (18.39 ± 2, p < 0.05), 
had no significant effect on the percentage of open arm 
entries (Fig. 3B) when compared to the epileptic alone 
rats. 
The anxiety ratio, which was calculated by dividing 
the percentage of time spent in open arm by the 
percentage of time spent in closed arm, was 
significantly higher in pilocarpine-treated rats (0.53 ± 
0.07 versus 0.23 ± 0.04 in control rats; p < 0.01; Fig. 
3C). In addition, entry ratio (percentage of open arm 
entry/percentage of closed entry) was significantly 
higher in epileptic rats (0.62 ± 0.12 versus 0.26 ± 0.04 
in control group, p < 0.05; Fig. 3D). 
Treatment with phenobarbital or p75 antagonist 
alone or combined treatment with p75 antagonist and 
phenobarbital significantly reduced the anxiety  
ratio (p < 0.05). However, only the decreasing effect  
of   combined    treatment   with   P75   antagonist   and 
phenobarbital on entry ratio was statistically significant 
(0.23 ± 0.03, p < 0.05; Fig. 3D), when compared to 
epileptic rats.   
 
 
 
                           
 
 
 
                         
 
 
Fig. 2. The results of 20-hour video monitoring of all groups indicating changes in the duration (A) and frequency (C) of 
spontaneous recurrent seizures. Histograms (B and D) indicate the average (± SEM) of duration and frequency of four different 
experimental groups. PT, pilo-treated; PP, pilo-pheno; PA, pilo-p75 anta; PAP, pilo-p75 anta + pheno 
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Fig. 3. Anxiety-related behaviors of pilocarpine-treated rats and the controls in the elevated plus-maze test. Behavioral testing was 
performed two weeks after the SE induction. (A) The percentage of time that the rats spent in the open arm; (B) the percentage of 
entrance of rats in the aversive open arms of the maze; (C) the anxiety and (D) entry ratios in different experimental conditions. 
*indicates the statistical difference from the control group (*p < 0.05; **p < 0.01) and †shows values different from the epileptic rats. 
 
 
 
Changes in mRNA expression of p75NTR and pro-
NGF in the hippocampus  
In the present work, the p75 receptor mRNA 
expression level was examined at one week, two 
weeks, and three weeks after induction of SE model. 
The results showed that the p75NTR expression was 
significantly higher in pilocarpine-induced epileptic 
model rats compared with that was seen in control 
group and reached to its highest level (2.9 ± 0.1, p < 
0.001) in the first week after the induction of model 
and then decreased at the second (2.1 ± 0.2) and the 
third weeks (2.07 ± 0.1) after SE induction. However, 
it was significantly higher than the control rats at all 
those time points (1 ± 0.06; Fig. 4A). Next, the pro-
NGF expression was examined after epileptic model 
induction. Interestingly, a similar expression pattern to 
the p7NTR was observed for pro-NGF mRNA 
expression in SE group. Within the first week after the 
induction of epileptic model, pro-NGF gene expression 
showed an initial significant increase at the first week 
(4.03 ± 0.2) when compared to the control (1 ± 0.081), 
and thereafter a decline in the expression was observed 
at the second (2.033 ± 0.08) and third (2.24 ± 0.1) 
weeks after SE induction (Fig. 4B). However, the 
expression level was still significantly higher than that 
of control group.  
 
 
DISCUSSION 
 
In line with previous investigations in epileptic 
rats
[42,44-46]
, we demonstrated here the up-regulation of 
mRNA expressions of p75NTR and pro-NGF in a rat 
pilocarpine-induced SE model, which in turn is 
associated with the elevated level of aggressive 
behavior.
  
  
Evidence has implied the role of p75NTR receptor 
and its ligands in the regulation and modulation of 
neurological and behavioral functions
[47-49]
. Some prior 
reports have also indicated that epilepsy often shows a 
comorbidity with behavioral disturbances, including 
aggression and agitation
[12,17,43]
, and induction   of    SE  
by   pilocarpine  can  also  provoke seizure-associated 
behaviors such as aggressive and unsocial responses. 
However, the open basis of this coincidence is not fully 
defined.  
The    present    results   indicated   that   pilocarpine- 
injected  rats   displayed   less  anxiety-like   behaviors, 
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Fig. 4. The levels of mRNA expression of p75NTR and pro-
NGF in the hippocampus of control and pilocapine-treated 
animals. (A) Data analysis showed significantly increase in 
p75NTR expression in pilocarpine-induced SE group at one 
week (***p < 0.001), two weeks, and three weeks (**p < 0.01) 
after pilocarpine injection compared to the control group. Its 
mRNA expression however was decreased at 2nd and 3rd weeks 
after pilocarpine-injection (††p < 0.01) compared to the first 
week. (B) The pro-NGF mRNA expression was significantly 
changed at one (***p < 0.001), two, and three weeks (**p < 0.01) 
after SE induction compared to the control group. However, its 
mRNA expression was significantly reduced at 2nd and 3rd 
weeks, when compared to the first week of SE induction (†††p < 
0.001). The mRNA expressions of p75NTR and pro-NGF were 
normalized to GAPDH and were expressed as mean ± SD, n = 4.  
 
 
which is consistent with previous published  
reports
[50-52]
 that demonstrated SE induction is 
associated with decreased anxiety in the elevated plus-
maze, as evidenced by longer time spent and higher 
number of entries in  arms. Similar to our finding, 
Detour and colleagues
[50]
 found that in the elevated 
plus maze, epileptic rats exhibited a significant higher 
number of entries and the time spent in open arms, 
suggesting a reduction in the anxiety-related behavior.  
This reduction has been attributed to the lesions in 
amygdala and hippocampus
[53-55]
.  
Increased expression of p75 neurotrophin receptor in 
response to seizure has been reported
[44]
. Increased 
expression of p75NTR
 
has also been reported in a 
variety of neurodegenerative diseases, which may be 
correlated to the cell fate
[56]
.
 
Here, the onset of seizure 
attacks was paralleled by changes in anxiety-related 
behavior, possibly due to the up-regulation of mRNA 
expression of the p75 receptor, which has a role in 
epilepsy and neuropsychiatric disorders. Epileptic 
patients suffer more frequently from psychiatric and 
behavioral disorders than the general population, which 
have a negative impact on their life quality
[6,57,58]
. 
Hence, the understanding of underlying mechanism is 
necessary for introduction of effective treatment 
strategy for behavioral disorders associated with 
epilepsy. 
Neurotrophins and their receptors have been reported 
to be involved in epileptogenesis using several animal 
models of epilepsy
[59-61]
. p75, which is normally 
expressed during development, has been shown to be 
re-expressed in adulthood under various pathological 
conditions, including epilepsy
[15,42]
. In addition, 
Volosin et al.
[44] 
have suggested a role for 
proneurotrophins acting through p75NTR in 
hippocampal cell death after seizure. Several 
documents have also suggested a pivotal role for 
neurotrophins and their receptors in various psychiatric 
disorders such as depression
[62-64]
. 
In the present study, we demonstrated that the up-
regulation of P75NTR and pro-NGF is associated with 
behavioral alterations following the induction of SE by 
pilocarpine, which is consistent with previous 
studies
[35,36]
. It has been shown that neurotrophin 
receptors, especially P75NTR, play an important role 
in epileptogenesis and are up-regulated in the animal 
model of epilepsy and epileptic patients
[65,66]
. 
Therefore, we asked whether the blockade of p75 
neurotrophin receptor may be a useful therapeutic 
target for the treatment of behavioral changes 
associated with epilepsy following SE induction. Our 
findings for the first time showed that i.p. injection of 
p75 antagonist (1 mg/kg), alone or combined with 
phenobarbital (30 mg/kg), significantly reduced the 
duration and the frequency of SRS. Furthermore, the 
blockade of p75NTR induced anxiogenic behavior in 
rats, evidenced by the decrease in the time spent in 
open arms and the decreased anxiety scores and entry 
ratio when compared with pilocarpine-treated rats in 
the elevated plus maze. Moreover, p75NTR inhibition 
attenuated the behavioral hyperexcitability, as 
indicated by lower scores in approach- and touch-
response as well as finger-snap and pick-up tests.  
In summary, our results suggest that the p75NTR 
blockade attenuates aggressive behavior in epileptic 
F
o
ld
 c
h
a
n
g
e 
in
 r
el
a
ti
v
e 
p
7
5
  
m
R
N
A
 e
x
p
re
ss
io
n
 l
ev
el
 
4 
 
3 
 
 
2 
 
 
1 
 
 
 0 
5 
 
 
4 
 
3 
 
 
2 
 
 
1 
 
 
 0 
 
 
F
o
ld
 c
h
a
n
g
e 
in
 r
el
a
ti
v
e 
p
ro
-N
G
F
  
m
R
N
A
 e
x
p
re
ss
io
n
 l
ev
el
 
Control                1                   2                   3  
Week after pilocarpine injection 
Control                1                    2                    3  
Week after pilocarpine injection 
(A) 
(B) 
D
ow
nl
oa
de
d 
fro
m
 ib
j.p
as
teu
r.a
c.i
r a
t 1
1:4
5 I
RD
T o
n W
ed
ne
sd
ay
 S
ep
tem
be
r 1
1th
 20
19
    
    
  [ 
DO
I: 1
0.2
92
52
/ib
j.2
2.4
.26
4 ]
  
P75NTR Blockade Alleviates Seizure-Related Behaviors Mehrabi et al. 
 
 
272 Iran. Biomed. J. 22 (4): 264-274 
 
rats, suggesting that the overexpression of p75NTR 
may be a possible mechanism of the development of 
aggression and seizures; therefore, its inhibition could 
be a potential therapeutic approach for psychiatric 
behaviors associated with epilepsy. 
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